Neurostimulation for appetite suppression

Elira, a startup from St. Louis, Missouri, recently received their second patent in the AI Biotech space. The company recognizes the issue of obesity in America, and believes they have a solution. They are focused on using a transcutaneous electric patch in driving weight loss and appetite suppression when coupled with an integrated weight loss reduction strategy. They seem to be one of the only using AI in this way. The company is currently wrapping up their second clinical trial (the first was terminated early) and results are expected within the next year. Depending on the results, this technology could both be developed further or expanded to other therapeutic areas.

Related Posts

Cala Health Claims to Have the only Patented Neurostimulation for Essential Tremor Treatment. The Patent Data Disagrees

Cala Health has figured out that innovations backed by patents make them exponentially more valuable in the marketplace. However, in a zest…


Capital One is Investing in AI Biotech? What’s in their wallet?

In the past 18 months, Capital One has expanded past its usual banking activities, and begun exploring the AI Biotech Sector. But do they…


Google AI Reinvents Speech Recognition. Who will follow?

There is no doubt that the big 5 tech companies (Apple, Amazon, Google, Facebook, and Microsoft) have developed massive IP portfolios in…